HPV 6/11, 16, 18 seroprevalence in men in two US cities

Sexually Transmitted Diseases

Volumn 36, Issue 11, 2009, Pages 671-674

  Dunne, Eileen F ^a   Nielson, Carrie M ^b,c   Hagensee, Michael E ^d   Papenfuss, Mary R ^e   Harris, Robin B ^c   Herrel, Nicholas ^d   Gourlie, Jennifer ^d   Abrahamsen, Martha ^e   Markowitz, Lauri E ^a   Giuliano, Anna R ^e  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CITY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; QUESTIONNAIRE; SEROPREVALENCE; SEXUAL BEHAVIOR; SMOKING; UNITED STATES; VIRUS ETIOLOGY; VIRUS INFECTION;

ADOLESCENT; ADULT; AGE FACTORS; ANTIBODIES, VIRAL; ARIZONA; FEMALE; FLORIDA; HETEROSEXUALITY; HUMAN PAPILLOMAVIRUS 11; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MALE; PAPILLOMA; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; QUESTIONNAIRES; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; SEXUAL PARTNERS; URBAN POPULATION;

EID: 70350754603     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e3181bc094b     Document Type: Article

References (17)

1. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518-527. (Pubitemid 36159887)
2. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118:3030-3044.
3. Carter JJ, Koutsky LA, Hughes JP, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000; 181:1911-1919.
4. Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent human papillomavirus vaccine: Recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2007; 56:1-24.
5. Giuliano A, Palefsky J; on behalf of the male quadrivalent HPV vaccine efficacy trial study group. The efficacy of quadrivalent HPV (Types 6/11/16/18) vaccine in reducing the incidence of HPV infection and HPV-related genital disease in young men. Abstract presented at: EUROGIN; 2008; Paris, France.
6. Dunne EF, Nielson CM, Stone KM, et al. Prevalence of HPV infection among men: A systematic review of the literature. J Infect Dis 2006; 194:1044-1057.
7. Newall AT, Brotherton JM, Quinn HE, et al. Population sero-prevalence of human papillomavirus types 6, 11, 16, and 18 in men, women, and children in Australia. Clin Infect Dis 2008; 46:1647-1655.
8. Jit M, Vyse A, Borrow R, et al. Prevalence of human papilloma-virus antibodies in young female subjects in England. Br J Cancer 2007; 97:989-991.
9. Markowitz Le, Sternberg LM, Dunne EF, McQuillan G, et al. Seroprevalence of human papillomavirus types 6, 11, 16 and 18 in the United States: National Health and Nutrician Examination Survey 2003-2004. J Infect Dis 2009; 105:9-67.
10. Nielson CM, Flores R, Harris RB, et al. Human papillomavirus prevalence and type distribution in male anogenital sites and semen. Cancer Epidemiol Biomarkers Prev 2007; 16:1107-1114.
11. Slavinsky J, Kissinger P, Burger L, et al. Seroepidemiology of low and high oncogenic risk types of human papillomavirus in a predominantly male cohort of STD clinic patients. Int J STD AIDS 2001; 12:516-523.
12. Stone KM, Karem KL, Sternberg MR, et al. Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis 2002; 186:1396-1402.
13. Hagensee ME, Kiviat N, Critchlow CW, et al. Seroprevalence of human papillomavirus types 6 and 16 capsid antibodies in homosexual men. J Infect Dis 1997; 176:625-631.
14. Thompson DL, Douglas JM Jr, Foster M, et al. Seroepidemiology of infection with human papillomavirus 16, in men and women attending sexually transmitted disease clinics in the United States. J Infect Dis 2004; 190:1563-1574.
15. Svare EI, Kjaer SK, Nonenmacher B, et al. Seroreactivity to human papillomavirus type 16 virus-like particles is lower in high-risk men than in high-risk women. J Infect Dis 1997; 176: 876-883.
16. Strickler HD, Kirk GD, Figueroa JP, et al. HPV 16 antibody prevalence in Jamaica and the United States reflects differences in cervical cancer rates. Int J Cancer 1999; 80:339-344.
17. Castellsague X, Munoz N. Chapter 3: Cofactors in human papillomavirus carcinogenesis-role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr 2003; 31:20-28.